Tien Liang BioTech Co., Ltd.
TPEX:4127 Rapporto sulle azioni
Aggiungi alla lista di controlloTien Liang BioTech Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Tien Liang BioTech ha un patrimonio netto totale di NT$474.2M e un debito totale di NT$105.0M, che porta il suo rapporto debito/patrimonio netto a 22.1%. Le sue attività totali e le sue passività totali sono rispettivamente NT$652.4M e NT$178.2M. L'EBIT di Tien Liang BioTech è NT$10.1M rendendo il suo rapporto di copertura degli interessi 10.2. Ha liquidità e investimenti a breve termine pari a NT$189.4M.
Informazioni chiave
22.1%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi 10.2x Contanti NT$189.45m Patrimonio netto NT$474.18m Totale passività NT$178.21m Totale attività NT$652.39m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Now 22% overvalued after recent price rise Oct 25
Now 22% overvalued Aug 28
Upcoming dividend of NT$0.50 per share Aug 20
Second quarter 2024 earnings released: NT$0.08 loss per share (vs NT$0.12 profit in 2Q 2023) Aug 17
First quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.14 in 1Q 2023) May 19
Investor sentiment deteriorates as stock falls 17% Apr 23
Full year 2023 earnings released: EPS: NT$39.00 (vs NT$1.30 in FY 2022) Apr 02
New minor risk - Share price stability Mar 22
Investor sentiment improves as stock rises 22% Mar 19
Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024 Mar 14
Third quarter 2023 earnings released: NT$0.03 loss per share (vs NT$0.20 profit in 3Q 2022) Nov 15
Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.22 in 2Q 2022) Aug 11
Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021) Nov 16
Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021) Nov 13
Investor sentiment deteriorated over the past week Jul 04
Investor sentiment improved over the past week Jun 06
Investor sentiment improved over the past week Apr 18
Full year 2021 earnings released: EPS: NT$1.02 (vs NT$1.13 loss in FY 2020) Mar 30
Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.39 loss in 2Q 2020) Aug 18
First quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.045 loss in 1Q 2020) May 17
Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt? Apr 19
Full year 2020 earnings released: NT$1.13 loss per share (vs NT$1.02 loss in FY 2019) Mar 31
New 90-day low: NT$10.55 Jan 20
Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt Jan 04
Third quarter 2020 earnings released: NT$0.40 loss per share Nov 14
New 90-day low: NT$10.60 Oct 15
New 90-day low: NT$10.80 Sep 30
New 90-day low - NT$11.45 Sep 14
First half earnings released Aug 16
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( NT$312.0M ) di 4127 superano le sue passività a breve termine ( NT$144.1M ).
Passività a lungo termine: Le attività a breve termine di 4127 ( NT$312.0M ) superano le sue passività a lungo termine ( NT$34.1M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 4127 ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di 4127 si è ridotto da 32.2% a 22.1% negli ultimi 5 anni.
Copertura del debito: Il debito di 4127 è ben coperto dal flusso di cassa operativo ( 58.7% ).
Copertura degli interessi: I pagamenti degli interessi sul debito di 4127 sono ben coperti dall' EBIT ( 10.2 x copertura).
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}